Studies have shown that decreased AMPK activity is associated with obesity and Type II Diabetes, while AMPK activity is increased with metabolically favorable conditions and cholesterol lowering drugs. This evidence concerns the gene PRKAA1 and obesity due to melanocortin 4 receptor deficiency.